Padcev-Keytruda Combo Lands Another Win in Bladder Cancer

(MedPage Today) — SAN FRANCISCO — Perioperative treatment with enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) significantly improved survival compared with standard neoadjuvant chemotherapy in patients with muscle-invasive bladder…